Contrasting Baudax Bio (OTCMKTS:BXRXV) & Imunon (NASDAQ:IMNN)

Baudax Bio (OTCMKTS:BXRXV) and Imunon (NASDAQ:IMNN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Institutional and Insider Ownership

4.5% of Imunon shares are owned by institutional investors. 5.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Baudax Bio and Imunon”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baudax Bio	N/A	N/A	N/A	N/A	N/A
Imunon	$500,000.00	18.05	-$19.51 million	($2.02)	-0.48

Baudax Bio has higher earnings, but lower revenue than Imunon.

Profitability

This table compares Baudax Bio and Imunon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baudax Bio	N/A	N/A	N/A
Imunon	N/A	-165.52%	-102.47%

Analyst Recommendations

This is a breakdown of recent recommendations for Baudax Bio and Imunon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baudax Bio	0	0	0	0	N/A
Imunon	0	0	1	1	3.50

Imunon has a consensus target price of $14.00, indicating a potential upside of 1,358.49%.

Summary

Imunon beats Baudax Bio on 5 of the 7 factors compared between the two stocks.

About Imunon

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.